0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Natural History of Valvular Regurgitation 1 Year after Discontinuation of Dexfenfluramine Therapy: A Randomized, Double-Blind, Placebo-Controlled Trial

Neil J. Weissman, MD; Julio A. Panza, MD; John F. Tighe Jr., MD; and John T. Gwynne, MD
[+] Article and Author Information

From Washington Hospital Center, Washington, D.C.; National Heart, Lung, and Blood Institute, Bethesda, Maryland; and Wyeth-Ayerst Research, Philadelphia, Pennsylvania.


Disclaimer:Dr. Panza's work in this study, including the preparation of the manuscript, was completed in his private capacity. The views expressed in this article do not necessarily represent those of the National Institutes of Health, the Department of Health and Human Services, or the United States.

Acknowledgments:The authors thank Susan Perras, MSN, Maria Mattern, RN, and Jan Kitzen, PhD, for coordination of the clinical trial, assistance with the literature review, and technical preparation of the manuscript; John Vance, MD, for thoughtful review of the manuscript; Harvey Kushner, PhD, for assistance in developing the statistical analysis plan and providing statistical support during the data analysis and manuscript preparation; and Jonathan Tall, CNMT, CCRC, and Kenneth Horton, RDCS, for coordination of the central echocardiography laboratory.

Grant Support:By a research grant from the Wyeth-Ayerst Research Division of Wyeth Laboratories, Philadelphia, Pennsylvania. Dexfenfluramine hydrochloride capsules (Redux) were manufactured and distributed by Wyeth Laboratories, Inc., a Wyeth-Ayerst Company, under license from Interneuron Pharmaceuticals, Inc., Lexington, Massachusetts.

Requests for Single Reprints:Neil J. Weissman, MD, Cardiovascular Research Institute, Washington Hospital Center, 110 Irving Street NW, Suite 4B-1, Washington, DC 20010.

Current Author Addresses:Dr. Weissman: Cardiovascular Research Institute, Washington Hospital Center, 110 Irving Street NW, Suite 4B-1, Washington, DC 20010.

Dr. Panza: Cardiology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10, Room 7B-15, Bethesda, MD 20892.

Dr. Tighe: Cardiology Consultants of Westchester, 3078 Route 9W South, Suite 100, New Windsor, NY 12553.

Dr. Gwynne: Department of Clinical Research, Wyeth-Ayerst Research, Wyeth-Ayerst, 145 King of Prussia Road, Radnor, PA 19087.

Author Contributions:Conception and design: N.J. Weissman, J.A. Panza, J.F. Tighe, J.T. Gwynne.

Analysis and interpretation of the data: N.J. Weissman, J.A. Panza, J.F. Tighe, J.T. Gwynne.

Drafting of the article: N.J. Weissman, J.A. Panza, J.F. Tighe, J.T. Gwynne.

Critical revision of the article for important intellectual content: N.J. Weissman, J.A. Panza, J.F. Tighe, J.T. Gwynne.

Final approval of the article: N.J. Weissman, J.A. Panza, J.F. Tighe, J.T. Gwynne.

Provision of study materials or patients: N.J. Weissman.

Statistical expertise: N.J. Weissman.

Obtaining of funding: N.J. Weissman, J.T. Gwynne.

Administrative, technical, or logistic support: N.J. Weissman, J.T. Gwynne.

Collection and assembly of data: N.J. Weissman, J.A. Panza, J.F. Tighe, J.T. Gwynne.


Ann Intern Med. 2001;134(4):267-273. doi:10.7326/0003-4819-134-4-200102200-00009
Text Size: A A A

Many studies have reported an association between use of appetite suppressants and cardiac valvular abnormalities (16). After the initial reports (1, 7), dexfenfluramine and fenfluramine were withdrawn from the market. Now that these drugs are no longer available, the most clinically relevant question is whether progression, regression, or latent development of valvular regurgitation is associated with appetite suppressants.

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Heart Valve Abnormalities 1 Year after Patients Stopped Taking the Weight-Loss Drug Dexfenfluramine

The summary below is from the full report titled “Natural History of Valvular Regurgitation 1 Year after Discontinuation of Dexfenfluramine Therapy. A Randomized, Double-Blind, Placebo-Controlled Trial.” It is in the 20 February 2001 issue of Annals of Internal Medicine(volume 134, pages 267-273). The authors are NJ Weissman, JA Panza, JF Tighe Jr., and JT Gwynne.

Read More...

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)